FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094761607> ?p ?o ?g. }

• W2094761607 endingPage "126" @default.
• W2094761607 startingPage "109" @default.
• W2094761607 abstract "Prostaglandins are formed from arachidonic acid by the action of cyclooxygenase and subsequent downstream synthetases. Two closely related forms of the cyclooxygenase have been identified which are now known as COX-1 and COX-2. Both isoenzymes transform arachidonic acid to prostaglandins, but differ in their distribution and their physiological roles. Meanwhile, the responsible genes and their regulation have been clarified. COX-1, the pre-dominantly constitutive form of the enzyme, is expressed throughout the body and performs a number of homeostatic functions such as maintaining normal gastric mucosa and influencing renal blood flow and platelet aggregation. In contrast, the inducible form is expressed in response to inflammatory and other physiological stimuli and growth factors, and is involved in the production of the prostaglandins that mediate pain and support the inflammatory process. All the classic NSAIDs inhibit both COX-1 and COX-2 at standard anti-inflammatory doses. The beneficial anti-inflammatory and analgesic effects are based on the inhibition of COX-2, but the gastrointestinal toxicity and the mild bleeding diathesis are a result of the concurrent inhibition of COX-1. Agents that inhibit COX-2 while sparing COX-1 represent a new attractive therapeutic development and could represent a major advance in the treatment of rheumatoid arthritis and osteoarthritis. Apart from its involvement in inflammatory processes, COX-2 seems to play a role in angiogenesis, colon cancer and Alzheimer's disease, based on the fact that it is expressed during these diseases. The benefits of specific and selective COX-2 inhibitors are currently under discussion and offer a new perspective for a further use of COX-2 inhibitors." @default.
• W2094761607 created "2016-06-24" @default.
• W2094761607 creator A5034203849 @default.
• W2094761607 creator A5086411867 @default.
• W2094761607 date "2001-02-01" @default.
• W2094761607 modified "2023-10-16" @default.
• W2094761607 title "Cyclooxygenase inhibitors – current status and future prospects" @default.
• W2094761607 cites W1025584546 @default.
• W2094761607 cites W1485442945 @default.
• W2094761607 cites W1494920110 @default.
• W2094761607 cites W1536031017 @default.
• W2094761607 cites W1536681507 @default.
• W2094761607 cites W1539392991 @default.
• W2094761607 cites W1598952686 @default.
• W2094761607 cites W1676314625 @default.
• W2094761607 cites W1899889608 @default.
• W2094761607 cites W1964520877 @default.
• W2094761607 cites W1964533656 @default.
• W2094761607 cites W1966358461 @default.
• W2094761607 cites W1967526789 @default.
• W2094761607 cites W1968104113 @default.
• W2094761607 cites W1972565634 @default.
• W2094761607 cites W1976060163 @default.
• W2094761607 cites W1981662925 @default.
• W2094761607 cites W1981819970 @default.
• W2094761607 cites W1985249377 @default.
• W2094761607 cites W1985804036 @default.
• W2094761607 cites W1985813197 @default.
• W2094761607 cites W1990030459 @default.
• W2094761607 cites W1993267975 @default.
• W2094761607 cites W1994378803 @default.
• W2094761607 cites W1995198341 @default.
• W2094761607 cites W1996223952 @default.
• W2094761607 cites W1997208118 @default.
• W2094761607 cites W1997861448 @default.
• W2094761607 cites W2000724113 @default.
• W2094761607 cites W2001214229 @default.
• W2094761607 cites W2001239671 @default.
• W2094761607 cites W2002511811 @default.
• W2094761607 cites W2004293605 @default.
• W2094761607 cites W2005823432 @default.
• W2094761607 cites W2006120055 @default.
• W2094761607 cites W2006512496 @default.
• W2094761607 cites W2008035988 @default.
• W2094761607 cites W2009132110 @default.
• W2094761607 cites W2012810767 @default.
• W2094761607 cites W2014007136 @default.
• W2094761607 cites W2015371826 @default.
• W2094761607 cites W2016120738 @default.
• W2094761607 cites W2017203125 @default.
• W2094761607 cites W2018983724 @default.
• W2094761607 cites W2019739489 @default.
• W2094761607 cites W2020092959 @default.
• W2094761607 cites W2020971441 @default.
• W2094761607 cites W2023200971 @default.
• W2094761607 cites W2026732117 @default.
• W2094761607 cites W2030850720 @default.
• W2094761607 cites W2031280080 @default.
• W2094761607 cites W2032113087 @default.
• W2094761607 cites W2032754552 @default.
• W2094761607 cites W2033498682 @default.
• W2094761607 cites W2034679499 @default.
• W2094761607 cites W2038410983 @default.
• W2094761607 cites W2043212150 @default.
• W2094761607 cites W2043579471 @default.
• W2094761607 cites W2045212950 @default.
• W2094761607 cites W2046501054 @default.
• W2094761607 cites W2049927555 @default.
• W2094761607 cites W2050591359 @default.
• W2094761607 cites W2051009681 @default.
• W2094761607 cites W2052022429 @default.
• W2094761607 cites W2052031498 @default.
• W2094761607 cites W2054456797 @default.
• W2094761607 cites W2059169203 @default.
• W2094761607 cites W2059830154 @default.
• W2094761607 cites W2061667020 @default.
• W2094761607 cites W2063144963 @default.
• W2094761607 cites W2066074947 @default.
• W2094761607 cites W2067007327 @default.
• W2094761607 cites W2078736915 @default.
• W2094761607 cites W2079406594 @default.
• W2094761607 cites W2080479705 @default.
• W2094761607 cites W2083651943 @default.
• W2094761607 cites W2083748640 @default.
• W2094761607 cites W2086735062 @default.
• W2094761607 cites W2088769385 @default.
• W2094761607 cites W2094142298 @default.
• W2094761607 cites W2094752831 @default.
• W2094761607 cites W2107359522 @default.
• W2094761607 cites W2113745276 @default.
• W2094761607 cites W2115350007 @default.
• W2094761607 cites W2120102288 @default.
• W2094761607 cites W2120285683 @default.
• W2094761607 cites W2121852158 @default.
• W2094761607 cites W2122355853 @default.
• W2094761607 cites W2132069490 @default.
• W2094761607 cites W2134732424 @default.
• W2094761607 cites W2164125112 @default.

• next